3-溴-7-甲氧基-1-萘腈 | 847505-83-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 中文名称: 3-溴-7-甲氧基-1-萘腈
• 英文名称: 3-bromo-7-methoxy-1-naphthonitrile
• 英文别名: 3-bromo-7-methoxynaphthalene-1-carbonitrile
• CAS: 847505-83-3
• 化学式: C₁₂H₈BrNO
• 分子量: 262.106
• InChiKey: GRKYKMLRLISEPI-UHFFFAOYSA-N

物化性质

• 沸点：
  380.5±22.0 °C(Predicted)
• 密度：
  1.54±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  33
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2926909090

反应信息

• 作为反应物：
  描述：

  3-溴-7-甲氧基-1-萘腈 在 吡啶盐酸盐 作用下， 反应 2.0h， 生成 3-溴-7-羟基-1-萘腈
  参考文献：
  名称：

  取代了6-苯基-2-萘酚。有效的和选择性的非甾体类17beta-羟基甾体脱氢酶（17beta-HSD1）抑制剂：设计，合成，生物学评估和药代动力学。

  摘要：

  17β-雌二醇（E2）与雌激素依赖性疾病的发生和发展有关。它的浓度主要受17beta-羟类固醇脱氢酶1型（17beta-HSD1）调节，该酶催化将弱雌激素雌酮（E1）还原为强效E2。因此，该酶是治疗激素依赖性疾病的重要靶标。合成了37种新型取代的6-苯基-2-萘酚，并评估了其对17beta-HSD1的抑制作用，对17beta-HSD2和雌激素受体（ER）α和β的选择性以及药代动力学特性。SAR研究表明，这些化合物最有可能根据结合模式B与活性位点结合，即与类固醇A环类似的6-苯基部分。虽然苯环上的取代会降低活性，

  DOI：

  10.1021/jm800367k
• 作为产物：
  描述：

  7-羟基-1-萘甲腈 在 溴 、 potassium carbonate 、 溶剂黄146 作用下， 以 丙酮 为溶剂， 反应 7.0h， 生成 3-溴-7-甲氧基-1-萘腈
  参考文献：
  名称：

  ERβ Ligands. 3. Exploiting Two Binding Orientations of the 2-Phenylnaphthalene Scaffold To Achieve ERβ Selectivity

  摘要：

  The 2-phenylnaphthalene scaffold was explored as a simplified version of genistein in order to identify ER selective ligands. With the aid of docking studies, positions 1, 4, and 8 of the 2-phenylnaphthalene template were predicted to be the most potentially influential positions to enhance ER selectivity using two different binding orientations. Both orientations have the phenol moiety mimicking the A-ring of genistein. Several compounds predicted to adopt orientations similar to that of genistein when bound to ERbeta were observed to have slightly higher ER affinity and selectivity than genistein. The second orientation we exploited, which was different from that of genistein when bound to ERbeta, resulted in the discovery of several compounds that had superior ER selectivity and affinity versus genistein. X-ray structures of two ER selective compounds (i.e., 15 and 47) confirmed the alternate binding mode and suggested that substituents at positions 1 and 8 were responsible for inducing selectivity. One compound (i.e., 47, WAY-202196) was further examined and found to be effective in two models of inflammation, suggesting that targeting ER may be therapeutically useful in treating certain chronic inflammatory diseases.

  DOI：

  10.1021/jm058173s

文献信息

• 17Beta-Hydroxysteroid Dehydrogenase Type 1 Inhibitors for the Treatment of Hormone-Related Diseases
  申请人：Hartmann Rolf

  公开号：US20100204234A1

  公开（公告）日：2010-08-12

  The invention relates to the use of non-steroidal 17beta-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment and prophylaxis of hormone-dependent, particularly estrogen-dependent, diseases. The invention further relates to suitable inhibitors and to a method for the production thereof.

  该发明涉及使用非甾体17β-羟基类固醇脱氢酶1抑制剂治疗和预防激素依赖性疾病，特别是雌激素依赖性疾病。该发明还涉及适当的抑制剂以及生产方法。
• Process for the synthesis of 3-(3-fluoro-4-hydroxyphenyl)-7-hydroxynaphthonitrile
  申请人：Wu Yanzhong

  公开号：US20050054870A1

  公开（公告）日：2005-03-10

  A process for making a compound of formula I and intermediate compounds thereof, wherein R 1 is CN, F or Cl; R 2 is H or Br; and R 3 and R 4 are each independently H or F. The compounds of formula I are useful in the treatment of chronic inflammatory diseases, such as rheumatoid arthritis.

  一种制备公式I化合物及其中间体化合物的方法，其中R1为CN、F或Cl；R2为H或Br；R3和R4分别独立地为H或F。公式I化合物在治疗慢性炎症性疾病，如类风湿性关节炎方面具有用途。
• A high-affinity subtype-selective fluorescent probe for estrogen receptor β imaging in living cells
  作者：Zhiye Hu、Lu Yang、Wentao Ning、Chu Tang、Qiuyu Meng、Jie Zheng、Chune Dong、Hai-Bing Zhou

  DOI：10.1039/c8cc00483h

  日期：——

  Estrogen receptor β (ERβ) has recently been identified as a pharmaceutical target in hormone replacement therapy for breast cancers. However, the biological function of ERβ in disease progression remains unclear. A highly ERβ-selective fluorescent probe (FPNM) was discovered exhibiting nanomolar affinity for ERβ with an ERβ/ERα selectivity as high as 80, which allowed specific labeling of intracellular

  雌激素受体β（ERβ）最近已被确定为乳腺癌荷尔蒙替代疗法的药物靶标。然而，ERβ在疾病进展中的生物学功能仍不清楚。发现具有高ERβ选择性的荧光探针（FPNM）对ERβ表现出纳摩尔摩尔亲和力，其ERβ/ERα选择性高达80，可以对细胞内ERβ进行特异性标记。此外，首次通过FPNM染色直接观察到各种细胞生物环境（例如前列腺癌（DU-145）或三阴性乳腺癌（MDA-MB-231））中不同的ERβ动态。
• 17Beta-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of hormone-related diseases
  申请人：Hartmann Rolf

  公开号：US08546392B2

  公开（公告）日：2013-10-01

  The invention relates to the use of non-steroidal 17beta-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment and prophylaxis of hormone-dependent, particularly estrogen-dependent, diseases. The invention further relates to suitable inhibitors and to a method for the production thereof.

  该发明涉及使用非甾体17β-羟基类固醇脱氢酶1抑制剂治疗和预防激素依赖性疾病，特别是雌激素依赖性疾病。该发明还涉及适当的抑制剂及其生产方法。
• PROCESS FOR THE SYNTHESIS OF 3-(3-FLUORO-4-HYDROXYPHENYL)-7-HYDROXYNAPHTHONITRILE
  申请人：Wyeth

  公开号：EP1663929A2

  公开（公告）日：2006-06-07